Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which blood thinner works best after heart device implant? new trial aims to find out

NCT ID NCT03568890

Disease control Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two approaches—short-term anticoagulation (stronger blood thinners) versus antiplatelet therapy (milder blood thinners)—to prevent clots on a device placed in the heart's left atrial appendage. The trial involves 510 adults who have had this procedure. The goal is to see which strategy better reduces device thrombosis, stroke, and bleeding over 60 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood thinners (rivaroxaban, dabigatran, apixaban, edoxaban, clopidogrel, or low-dose aspirin)
What this could lead to
If it works, this could show that short-term blood thinners are better at preventing dangerous clots on the device after a heart procedure, reducing stroke risk.
What could go wrong
This is a phase 4 trial, so the drugs are already approved, but the best strategy for this specific use is still unknown. Results may not apply to all patients or devices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 510 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2018

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Successful transcatheter LAAC with any approved device * Age≥18 years old Exclusion Criteria: * Absolute contraindications for anticoagulation therapy * Absolute contraindications for antiplatelet therapy * End-stage renal disease (CrCl \<15 ml/min) * Recent percutaneous revascularization with drug-eluting stents requiring dual antiplatelet therapy * Prior intracranial hemorrhage * Contraindications for TEE * Severe pericardial effusion within the first 24 hrs following LAAC * Major/life-threatening bleeding event within the month prior to LAAC * Multiple bleeding events (minor or major) within the month prior to LAAC * Major/life-threatening bleeding within the first 24 hrs following LAAC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Hemorrhage hemorrhagic disease stroke disorder thrombotic disease transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding Left atrial appendage closure Stroke Thrombosis TIA

Contacts and locations

Locations

  • Josep Rodes-Cabau

    Québec, Quebec, G1V 4G5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.